<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239443</url>
  </required_header>
  <id_info>
    <org_study_id>HNCHIIT001</org_study_id>
    <nct_id>NCT04239443</nct_id>
  </id_info>
  <brief_title>Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer</brief_title>
  <official_title>Peripheral Circulating Blood Tumor Cells (CTC) Detection and CTC-based PD-L1 Antibody Immunofluorescence Detection to PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Second-line and Back-line Treatment of Advanced NSCLC, Soft Tissue Sarcoma, Uterine Cancer Clinical Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this one-arm study, histologically or cytologically confirmed advanced NSCLC, uterine&#xD;
      malignancies, and soft tissue sarcoma will be enrolled to investigate the efficacy and safety&#xD;
      of PD-1 monoclonal antibody SHR-1210 and apatinib, at the same time, peripheral circulating&#xD;
      blood tumor cells (CTC) detection and CTC-based PD-L1 antibody immunofluorescence detection&#xD;
      will be performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome:&#xD;
&#xD;
        1. Analysis of baseline levels of CTC and CTC PD-L1 and prognosis efficacy of patients:&#xD;
           Objective remission rate (ORR), progression free survival (PFS), overall survival (OS);&#xD;
&#xD;
        2. Dynamic monitoring of CTC and CTC PD-L1 at baseline before treatment, after two cycles&#xD;
           of treatment, and as the disease progresses.&#xD;
&#xD;
        3. Consistency analysis of PD-L1 and CTC PD-L1 expression in tissue specimens.&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      Duration of response(DOR), Disease control rate(DCR), Safety of the combination therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients fulfilling Eligibility Criteria will be included in our study. NSCLC participants will be given intravenous administration of SHR-1210 (200mg/2w) and oral of Apatinib (250mg/d) , soft tissue sarcoma will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (500mg/d), and uterine cancer will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (250mg/d).&#xD;
Treatments will be administrated until disease progression, death, or unacceptable toxicity.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective remission rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of Circulating Tumor Cell (CTC)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of PD-L1 expression on Circulating Tumor Cell (CTC) and tumor tissue</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response(DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Advanced Non Small Cell Lung Cancer</condition>
  <condition>Uterine Cancer</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>SHR1210 and Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC participants will be given intravenous administration of SHR-1210 (200mg/2w) and oral of Apatinib (250mg/d) , soft tissue sarcoma will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (500mg/d), and uterine cancer will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (250mg/d).&#xD;
The duration of treatment will till the disease progression, death, or unacceptable toxicity show up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 inhibitor</intervention_name>
    <description>Intravenous administration of SHR1210 (200mg/2weeks or 200mg/3weeks)</description>
    <arm_group_label>SHR1210 and Apatinib</arm_group_label>
    <other_name>Camrelizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>NSCLC and Uterine cancer will be given oral of Apatinib (250mg/d), soft tissue sarcoma will be given oral of Apatinib (500mg/d).</description>
    <arm_group_label>SHR1210 and Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 years, both men and women (Uterine cancer limited to women);&#xD;
&#xD;
          2. NSCLC: Pathologically confirmed advanced (IIIB, stage IV) NSCLC with at least 1&#xD;
             measurable lesion that meets the RECIST v1.1 standard without local treatment, of&#xD;
             which stage IIIb patients are incapable, unsuitable for surgery or radical&#xD;
             radiotherapy, NSCLC patients have failed at least the first-line standard treatment or&#xD;
             refused to receive standard treatment, or chemotherapy intolerance, Among them,&#xD;
             patients with sensitive gene mutations must fail after TKI treatment (patients who&#xD;
             have failed first-line or second-line treatment may participate in this study),&#xD;
             Patients with EGFR and ALK mutations must undergo EGFR and ALK inhibitor treatment&#xD;
             failure and EGFR T790M mutation negative, for EGFR T790M-positive patients,&#xD;
             third-generation EGFR TKI treatment fails.&#xD;
&#xD;
          3. Soft tissue sarcoma: Patients with distant metastasis or locally advanced disease who&#xD;
             have previously failed chemotherapy or sensitive recurrence or metastasis to soft&#xD;
             tissue sarcoma. Subjects who have judged by the investigator to be unsuitable for&#xD;
             surgical treatment (including amputation) of soft tissue sarcomas (diagnosed&#xD;
             pathologically or cytologically, but excluding gastrointestinal stromal tumors,&#xD;
             chondrocyte-bone tumors, embryonic/acinar rhabdomyosarcoma, Juventus Sarcoma,&#xD;
             extensive distant metastatic soft tissue tumors such as keloid cutaneous fibrosarcoma&#xD;
             and inflammatory myofibroblastic sarcoma, malignant peripheral nerve sheath tumor,&#xD;
             keloid cutaneous fibrosarcoma, inflammatory myofibroblastic sarcoma, malignant&#xD;
             interstitial Dermatoma) (priority consideration: synovial sarcoma, undifferentiated&#xD;
             multiline sarcoma, dedifferentiated liposarcoma), and measurable lesions that meet the&#xD;
             RECIST 1.1 standard.&#xD;
&#xD;
          4. Uterine cancer: Pathologically confirmed uterine cancer, including cervical cancer&#xD;
             (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma), endometrial&#xD;
             cancer, and uterine sarcoma, at least one measurable lesion that meets RECIST 1.1&#xD;
             criteria, recurrence/Persons with persistent cervical cancer, endometrial cancer, and&#xD;
             uterine sarcoma cannot be cured by surgery and/or radiotherapy, have received at least&#xD;
             a first-line treatment for advanced (stage IVB), recurrent/persistent cervical cancer,&#xD;
             endometrial cancer, uterine sarcoma Systemic chemotherapy patients (qualified to&#xD;
             participate in this study after the progress of first-line chemotherapy).&#xD;
&#xD;
          5. All acute toxicity caused by previous antitumor treatments were alleviated to level&#xD;
             0-1 (according to NCI CTCAE version 4.03) or to the level specified by the enrollment/&#xD;
             exclusion criteria 1 day before the first dose except for subjects whose toxicity does&#xD;
             not pose a safety risk);&#xD;
&#xD;
          6. Able to provide tumor samples (at least 20 unstained tumor samples or fresh tissue&#xD;
             specimens embedded in formalin-fixed paraffin within six months, 4ml of peripheral&#xD;
             blood samples before treatment and each effect evaluation);&#xD;
&#xD;
          7. ECOG score: 0-1, patients with soft tissue sarcoma amputation can be relaxed to 2&#xD;
             points;&#xD;
&#xD;
          8. Expected survival ≥ 12 weeks;&#xD;
&#xD;
          9. The function of important organs meets the following requirements (excluding the use&#xD;
             of any blood components and cell growth factors during screening);&#xD;
&#xD;
               1. Absolute neutrophil count ≥1.5 × 109 / L;&#xD;
&#xD;
               2. platelets ≥100 × 109/L;&#xD;
&#xD;
               3. Hemoglobin ≥9g/dL;&#xD;
&#xD;
               4. serum albumin ≥3g/dL;&#xD;
&#xD;
               5. total bilirubin ≤ 1.5ULN;&#xD;
&#xD;
               6. ALT and AST ≤1.5ULN;&#xD;
&#xD;
               7. AKP ≤ 2.5ULN;&#xD;
&#xD;
               8. Serum creatinine ≤ 1.5ULN or creatinine clearance ≥ 60mL/min;&#xD;
&#xD;
         10. Non-surgical sterilization female patients;&#xD;
&#xD;
         11. Participants volunteered to participate in the study, signed informed consent, good&#xD;
             compliance, and cooperated with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants who had any active autoimmune disease or a history of autoimmune disease&#xD;
             (such as the following, but not limited to: autoimmune hepatitis, interstitial&#xD;
             pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis,&#xD;
             nephritis , Hyperthyroidism, decreased thyroid function; subjects with vitiligo or&#xD;
             childhood asthma has completely resolved, adults can be included without any&#xD;
             intervention; subjects with bronchodilators for medical intervention can not be&#xD;
             included in asthma;&#xD;
&#xD;
          2. Participants who were treated with immunosuppressive agents, or systemic or absorbable&#xD;
             local hormones for immunosuppressive purposes (dose&gt;10mg/day, prednisone or other&#xD;
             curative hormones), and continued to use it within 2 weeks before enrollment;&#xD;
&#xD;
          3. Excessive allergic reactions to other monoclonal antibodies;&#xD;
&#xD;
          4. Participants who had clinical symptoms of central nervous system metastases (such as&#xD;
             brain edema, require hormonal intervention, or progress of brain metastases).&#xD;
             Participants who had previously received brain or meningeal metastasis treatment, such&#xD;
             as clinical stability (MRI) that has been maintained for at least 1 month, and have&#xD;
             stopped systemic hormonal therapy (dose&gt; 10 mg / day prednisone or other therapeutic&#xD;
             hormone) can be included;&#xD;
&#xD;
          5. Imaging (CT or MRI) showed that the tumor invades or demarcates large blood vessels.&#xD;
&#xD;
          6. Imaging (CT or MRI) showed obvious hollow or necrotic tumors in the lungs; those with&#xD;
             marginal adenocarcinoma with cavities can be considered after discussion with the&#xD;
             clinician.&#xD;
&#xD;
          7. Participants who had high blood pressure and cannot be well controlled with&#xD;
             antihypertensive medication (systolic blood pressure ≥140mmHg or diastolic blood&#xD;
             pressure ≥90 mmHg).&#xD;
&#xD;
          8. Participants who had poorly controlled clinical symptoms or diseases of the heart,&#xD;
             such as: (1) heart failure above NYHA 2 (2) unstable angina pectoris (3) myocardial&#xD;
             infarction within 1 year (4) clinically significant supraventricular Sexual&#xD;
             arrhythmias require treatment or intervention.&#xD;
&#xD;
          9. Participants who had abnormal blood coagulation (PT&gt; 16s, APTT&gt; 43s, TT&gt; 21s, Fbg &lt;2g&#xD;
             / L), bleeding tendency or receiving thrombolytic or anticoagulation；&#xD;
&#xD;
         10. Urine routine indicates urinary protein ≥ ++, or confirms that 24-hour urine protein&#xD;
             is ≥1.0 g；&#xD;
&#xD;
         11. Participants who previously received radiotherapy, chemotherapy, hormone therapy,&#xD;
             surgery or molecular targeted therapy. After treatment is completed (last dose),&#xD;
             subjects less than 4 weeks before study medication (or 5 drug half-life, whichever is&#xD;
             longer) Patients who did not recover from adverse events (excluding hair loss) from&#xD;
             previous treatment to ≤CTCAE 1 degree；&#xD;
&#xD;
         12. Clinically ascites or pleural effusion requiring therapeutic puncture or drainage；&#xD;
&#xD;
         13. Participants who had obvious cough blood in the first 2 months of randomization, or a&#xD;
             day with hemoptysis of half teaspoon (2.5ml) or more；&#xD;
&#xD;
         14. Participants who had clinically significant bleeding symptoms or have a clear bleeding&#xD;
             tendency within the first 3 months of randomization, such as gastrointestinal&#xD;
             bleeding, hemorrhagic gastric ulcer, fecal occult blood at baseline and above, or have&#xD;
             vasculitis；&#xD;
&#xD;
         15. Participants who had arterial/venous thrombotic events such as cerebrovascular&#xD;
             accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral&#xD;
             infarction), deep vein thrombosis and pulmonary embolism occurred within the first 6&#xD;
             months；&#xD;
&#xD;
         16. Participants who had known hereditary or acquired bleeding and thrombotic tendency (eg&#xD;
             hemophilia, coagulopathy, thrombocytopenia, hypersplenism, etc.)；&#xD;
&#xD;
         17. Participants who had an active infection or an unexplained fever during the screening&#xD;
             period before the first dose&gt; 38.5 degrees;&#xD;
&#xD;
         18. Patients with past and current objective evidence of pulmonary fibrosis, interstitial&#xD;
             pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe&#xD;
             impairment of lung function, etc;&#xD;
&#xD;
         19. Participants who had congenital or acquired immune deficiency (such as HIV-infected&#xD;
             persons), or positive for syphilis spiral antibodies, or active hepatitis (HBV&#xD;
             reference: HBsAg positive, and HBV DNA detection exceeds the upper limit of normal&#xD;
             values; (And the HCV virus titer detection value exceeds the upper limit of normal&#xD;
             value);&#xD;
&#xD;
         20. Participants who have used other drugs in clinical trials within 4 weeks before the&#xD;
             first use;&#xD;
&#xD;
         21. Participants has previous or concurrent other malignancies (except cured skin basal&#xD;
             cell carcinoma and cervical carcinoma in situ);&#xD;
&#xD;
         22. Participants may receive other systemic anti-tumor treatments during the study;&#xD;
&#xD;
         23. Participants with bone metastases who had received palliative radiation therapy within&#xD;
             4 weeks before participating in the study;&#xD;
&#xD;
         24. Participants who have previously received other PD-1 antibody treatments or other&#xD;
             immunotherapy against PD-1/PD-L1 or VEGFR single-target/multi-target inhibitors, such&#xD;
             as Sunitinib, Sorafeni, Bevacizumab, Anlotinib, Famitinib, Apatinib, and Reginafinib&#xD;
             (in advanced NSCLC, there is no need to exclude previous VEGFR single / multitarget&#xD;
             inhibitor Patients treated, but need to be discontinued for more than 4 weeks);&#xD;
&#xD;
         25. Live vaccine may be given less than 4 weeks before study medication or possibly during&#xD;
             the study;&#xD;
&#xD;
         26. According to the researcher's judgment, Participants has other factors that may lead&#xD;
             to the termination of the study. Serious diseases (including mental illness) require&#xD;
             combined treatment. There are serious laboratory abnormalities, accompanied by family&#xD;
             or social factors. To the safety of the subject, or the collection of information and&#xD;
             samples;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nong Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kunyan Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jing Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gang Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nong Yang</last_name>
    <phone>+8613055193557</phone>
    <email>yangnong0217@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunan cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nong Yang</last_name>
      <phone>+8613055193557</phone>
      <email>yangnong0217@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>PD-1 checkpoint inhibitor</keyword>
  <keyword>circulating blood tumor cells (CTC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>please contact the principal investigator of this study or correspondence author of published work.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

